Ozempic vs Zepbound: Selective vs Dual, Plus Sleep Apnea

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The PlexusDx Education Hub connects GLP-1 medicines, weight-management protocols, and the genetics that sit beneath every metabolic decision. Open the Peptides & GLP-1 library.

This review is written independently. PlexusDx maintains no commercial relationship with Novo Nordisk or Eli Lilly, and neither company had any input into this page.

Ozempic and Zepbound often surface together in searches, but they come from different molecules and different eras of the incretin category. One is a long-established GLP-1 selective agent; the other is a newer dual agonist whose approved uses now reach beyond metabolism. This comparison reflects publicly available information as of April 2026.

A GLP-1 mainstay meets a dual-agonist newcomer

Ozempic is a selective GLP-1 receptor agonist from Novo Nordisk built on semaglutide. Zepbound is a dual GIP and GLP-1 receptor agonist from Eli Lilly built on tirzepatide. They occupy the same broad class, yet Zepbound activates a second incretin receptor that Ozempic does not touch.

Selective versus dual incretin receptor engagement

Both compounds engage the GLP-1 receptor throughout the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, softening post-meal glucose spikes, and strengthening satiety cues. Zepbound adds agonism at the glucose-dependent insulinotropic polypeptide receptor, and that extra GIP activity is the central molecular distinction between a selective and a dual agonist here.

From diabetes roots to a sleep-apnea indication

Ozempic was FDA-approved for type 2 diabetes in 2017. Zepbound was FDA-approved for chronic weight management in 2023 in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, and in 2024 the FDA expanded its indication to include moderate-to-severe obstructive sleep apnea in adults with obesity. Indication breadth affects prescribing and coverage.

Evidence trails: SUSTAIN and SURMOUNT

Ozempic was evaluated in the SUSTAIN program for glycemic and cardiovascular outcomes. Zepbound was evaluated in the SURMOUNT program for chronic weight management, including SURMOUNT-OSA for obstructive sleep apnea. Some indirect comparisons exist, and SURPASS tested tirzepatide against semaglutide 1 mg in type 2 diabetes, but differing endpoints mean the cleanest interpretation stays per-trial.

Comparable safety under a class-wide warning

Both compounds carry the GLP-1 class boxed warning connected to thyroid C-cell tumor risk observed in rodent studies. Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are the most common for either, peaking during dose escalation. Reported serious events across the class include pancreatitis, gallbladder complications, and acute kidney injury tied to dehydration.

Monthly cost at U.S. list price

As of April 2026, Ozempic runs approximately $968–$1,029 per month (Novo Nordisk published pricing) and Zepbound approximately $1,059 per month (Eli Lilly published pricing). Real out-of-pocket cost turns on insurance coverage, manufacturer savings cards, the FDA indication on the prescription, and whether a compounded alternative exists through a licensed compounding pharmacy pathway.

The genetic terrain both compounds share

Regardless of which compound a clinician chooses, the underlying genetic architecture overlaps. Variants in GIPR shape the GIP arm that tirzepatide recruits, while GLP1R and FTO influence baseline appetite regulation, satiety, and energy expenditure. These pathway-level variants do not forecast response to any one product, but they map the biology any incretin compound is asked to modify.

PlexusDx offers semaglutide through its Weight Management Protocols, including the Semaglutide protocol. The upstream genetic context is the differentiator. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including GIPR, GLP1R, and FTO variants that shape your incretin, appetite, and energy-balance biology. Reading that profile alongside a protocol is the test before you invest approach.

Related reading on PlexusDx: Ozempic How to Use, Generic for Ozempic, Price of Ozempic, Ozempic Diabetes.

Disclaimer: This article is educational. PlexusDx offers semaglutide through its Weight Management Protocols, and this page covers the mechanism, evidence, and genetic context that inform any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare formats in the Weight Management Protocols collection, or start with the Precision Peptide Genetic Test to understand your incretin biology first.

Frequently Asked Questions about Ozempic and Zepbound

Is Zepbound approved for anything Ozempic is not?

Yes. Zepbound is FDA-approved for chronic weight management and, since 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity. Ozempic is approved for type 2 diabetes. The two products carry different labeled indications, which is one of the clearest practical distinctions between them beyond their molecular design.

Why is Zepbound a dual agonist and Ozempic is not?

Zepbound is built on tirzepatide, which engages both the GIP and GLP-1 receptors, while Ozempic is built on semaglutide, which engages only the GLP-1 receptor. That is a difference in molecular design chosen during development, not a dose difference, and it defines the selective-versus-dual distinction in this category.

Will the genetic test tell me which one to take?

No. The Precision Peptide Genetic Test does not predict response to Ozempic, Zepbound, or any medication. It analyzes pathway-level variants such as GIPR, GLP1R, and FTO that describe your baseline incretin and energy-balance biology, giving upstream context that applies whichever compound a provider ultimately recommends.

Are their side effects meaningfully different?

The profiles are broadly similar across the class, with gastrointestinal symptoms most common and most pronounced during dose escalation. Dual agonists may show slightly higher rates of certain GI effects in some trials. Both carry the class-wide thyroid C-cell warning, so discuss your full history with a provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.